Another article published in Headache examined the effects of onabotulinumtoxinA on depression when used as a treatment for the prevention of chronic migraine. The retrospective study evaluated patient reported outcomes before and after at least 2 sessions of onabotulinumtoxinA (onabot) injections. The researchers reviewed 429 patients who received the injections from 2010 to 2014. They found that 127 patients who had completed a patient health questionnaire-9 (PHQ-9) showed improvement in their depression scores while Headache Impact Test (HIT6) scores also improved significantly. As a result, the researchers surmised that onabot injections, in addition to helping with chronic migraine, improved scores on indicators of depression. However, it is not clear from this study whether the impact was due to the fact that patients’ headaches were also improved or if this is an independent finding.3
1. Buettner C, Nir RR, Bertisch SM, et al. Simvastatin and Vitamin D for Migraine Prevention: A Randomized Controlled Trial. Ann Neurol. 2015; doi:10.1002/ana.24534.
2. Cousins S, Ridsdale L, Goldstein LH, Noble AJ, Moorey S, Seed P. A pilot study of cognitive behavioural therapy and relaxation for migraine headache: a randomised controlled trial. J Neurol. 2015; doi:10.1007/s00415-015-7916-z.
3. Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. Headache. 2015;55(9):1218-24.
This article originally appeared on Neurology Advisor